| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
113,340,000 |
| Market
Cap: |
128.07(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6758 - $2.77 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
41,140 |
41,140 |
| Total Buy Value |
$0 |
$0 |
$49,985 |
$49,985 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
255,827 |
267,169 |
308,707 |
975,987 |
| Total Sell Value |
$306,355 |
$315,908 |
$380,503 |
$4,268,294 |
| Total People Sold |
6 |
6 |
6 |
8 |
| Total Sell Transactions |
19 |
22 |
33 |
58 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2023-03-01 |
4 |
S |
$3.03 |
$34,045 |
D/D |
(11,239) |
210,687 |
|
46% |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2023-03-01 |
4 |
S |
$3.03 |
$20,835 |
D/D |
(6,878) |
146,122 |
|
46% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-03-01 |
4 |
S |
$3.03 |
$100,064 |
D/D |
(33,033) |
823,622 |
|
46% |
|
| Mitchener Stephen |
SVP, Chief Business Officer |
• – – |
2023-03-01 |
4 |
S |
$3.03 |
$19,257 |
D/D |
(6,357) |
128,313 |
|
46% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-03-01 |
4 |
S |
$3.03 |
$33,942 |
D/D |
(11,205) |
245,361 |
|
46% |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
165,000 |
|
- |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
221,926 |
|
- |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
153,000 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
252,000 |
856,655 |
|
- |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
95,000 |
159,131 |
|
- |
|
| Mitchener Stephen |
SVP, Chief Business Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
134,670 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
95,000 |
256,566 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-02-27 |
4 |
S |
$3.04 |
$8,509 |
D/D |
(2,802) |
161,566 |
|
48% |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2023-02-15 |
4 |
S |
$3.16 |
$18,717 |
D/D |
(5,869) |
64,131 |
|
49% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-02-06 |
4 |
S |
$3.40 |
$13,430 |
D/D |
(3,950) |
604,655 |
|
39% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-02-06 |
4 |
S |
$3.40 |
$14,079 |
D/D |
(4,141) |
164,368 |
|
39% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-01-04 |
4 |
S |
$3.27 |
$12,825 |
D/D |
(3,922) |
608,605 |
|
27% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2022-12-05 |
4 |
S |
$5.17 |
$18,043 |
D/D |
(3,490) |
612,527 |
|
12% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2022-11-04 |
4 |
S |
$4.54 |
$15,858 |
D/D |
(3,493) |
616,017 |
|
26% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2022-10-04 |
4 |
S |
$5.87 |
$20,475 |
D/D |
(3,488) |
619,510 |
|
38% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2022-09-08 |
4 |
S |
$5.23 |
$18,196 |
D/D |
(3,479) |
622,998 |
|
37% |
|
| Mitchener Stephen |
SVP, Chief Business Officer |
• – – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
70,546 |
|
- |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
119,949 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
168,509 |
|
- |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
83,000 |
|
- |
|
592 Records found
|
|
Page 3 of 24 |
|
|
0.05 (4.63%) 
